Freshly isolated human adipocytes showed specific uptake of 125I-labeled human high density lipoprotein (HDL2 and HDL3), a portion of which could be released by subsequent incubation with excess unlabeled ligand. To study the 
binding, sucrose gradient-purified adipocyte plasma membranes were incubated with radioiodinated lipoprotein particles under equilibrium conditions in the absence (total binding) or presence (nonspecific binding) of 100-fold excess unlabeled ligand. Specific binding of HDL2 and HDL3, calculated by subtracting nonspecific from total binding, was Ca"+ independent, unaffected by EDTA, and not abolished by pronase treatment of the membranes. Modification of HDL3 by reductive methylation or cyclohexanedione treatment also failed to affect its binding to adipocyte plasma membranes. High salt concentration (200 mM NaCG) inhibited specific binding of HDL2 and HDL3 but had no effect on LDL binding. A significant portion of 125I1 HDL2 or 125I-HDL3 binding was consistently inhibited by adding excess unlabeled LDL, but this inhibition was incomplete as compared with a similar molar excess of unlabeled HDL2 or HDL3.
The role of apoproteins (apo) in HDL binding to adipocyte membranes was examined by comparing binding of HDL2 and HDL3 isolated from normal, abetalipoproteinemic (abeta) and apo E-deficient (apo Eo) plasma. Specific binding was observed with all normal and mutant HDL particles. Furthermore, a significant portion (61-78%) of abeta-HDL2, apo EO-HDL2, and apo EO-HDL3 binding was inhibited by adding 100-fold excess of unlabeled low density lipoproteins (LDL). The crosscompetition of LDL and HDL binding was confirmed by the ability of normal, abeta, and apo EO-HDL2 to completely inhibit '25I-LDL binding. These data suggest that HDL binding is independent of apo E and that the responsible apoprotein(s) of HDL compete with LDL-apo B for binding to 
Introduction
Plasma high density lipoproteins (HDL)' are critically important in the metabolism of cellular cholesterol, as these particles are believed to act as efflux acceptors of cholesterol from peripheral tissues for excretion by the liver (1, 2) and also deliver cholesterol to steroidogenic tissues for hormone synthesis (3) (4) (5) (6) (7) (8) . Variations in plasma HDL concentrations have clinical implications, in that low concentrations of HDL are associated with enhanced risk for premature atherosclerosis, whereas high concentrations indicate some protection against the future development of coronary artery disease (9, 10) .
The catabolic mechanisms and sites of HDL particle interaction in man remain to be defined. Several reports have shown specific high-affinity binding sites for HDL in steroidogenic tissues of rodents (11) (12) (13) (14) (15) , especially the adrenal and gonads. Specific binding of human HDL to hepatocytes (16-18), intestinal mucosal cells (19) , as well as cultured human skin fibroblast systems (20) (21) . In the rat, the principal tissue sites of degradation of HDL as monitored by labeled apoprotein (apo) Al are kidney, liver, skin, small intestine, and adipose tissue, in descending order of quantitative significance (21) . The sites of HDL catabolism in man are not known, and in vivo assessment using existing methods is not feasible. Alternatively, analysis of tissue biopsy specimens can provide some insight into lipoprotein receptor status and may approximate in vivo characteristics. Several studies have been carried out using human tissue biopsy specimens showing the presence of low density lipoprotein (LDL) and HDL receptors in liver (22) and adipose cells (23) .
Human adipose tissue is an important cholesterol storage organ, but does not synthesize significant amounts of cholesterol de novo (24, 25) . The flux of cholesterol in this tissue is thus mediated by interaction with lipoproteins. In previous studies from this laboratory, high-affinity specific binding of LDL was shown in freshly isolated human adipocytes (23) and purified plasma membranes (26) . Specificity was not absolute, in that human HDL2 and HDL3 both competed effectively with the LDL binding site (23, 26) . This observation implied the presence of binding sites for HDL on adipocytes, and the fact that adipose tissue in man is a large organ (24) indicated that adipose tissue could be an important site of HDL interactions in man despite its quantitative insignificance in the rat (21) .
In the present study, we examined in detail the interactions of purified adipocyte plasma membranes from freshly isolated adipocytes with a variety of HDL particles isolated from normal subjects and from patients with genetic apoprotein deficiencies. These studies suggest that interactions of human adipocytes with HDL involve specific binding sites for apo Al and/or apo All, and are independent of apo E. (27) . Apo E-free HDL2 and HDL3 (apo EO) were isolated from plasma of a patient genetically deficient in apo E (28) . Lipoproteins free of apo B were isolated from plasma of a patient with abetalipoproteinemia (29) .
Methods
All lipoproteins used in the present study were washed once by ultracentrifugation and dialyzed against 0.15 M NaCl and 1 mM EDTA, pH 8.6. Lipoproteins were analyzed by agarose gel electrophoresis (Beckman Paragon electrophoresis system) and by SDS polyacrylamide gel electrophoresis (30 The above isolation procedure yielded on the average 101.5±9.6-,g membrane protein/106 cells.
The purity of the plasma membrane fraction was examined by enzyme marker assays. 5' nucleotidase (36), succinic dehydrogenase (37), acid phosphatase (38) , and NADH dehydrogenase (39) were measured as previously described. The purified adipocyte membranes were found to be 3-5-fold higher in 5' nucleotidase activity compared with cell homogenate, and contained negligible mitochondrial, lysosomal, and microsomal contamination. It was also observed that lipoprotein binding activities of the purified plasma membranes remained unchanged throughout a storage period of 3 mo at -20°C.
Lipoprotein uptake and degradation by adipocytes. Freshly isolated adipocytes were incubated with shaking at 37°C in l-oz plastic bottles in 2 ml KRB buffer containing 5% BSA (KRBA), 5 mM glucose, 25I-labeled lipoprotein, and 2.5 ug/ml lima bean trypsin inhibitor. Previous studies (23) have indicated that inclusion of trypsin inhibitor in the assay reduces nonspecific degradation of lipoprotein. After 4 h of incubation, the medium and cells were separated and the cells were washed four times with 3 ml KRBA. The cells were then denatured with 5 ml 10% TCA and heated at 80°C for 10 min. The TCA precipitate and supernatant were delipidated and the organic extracts were pooled and used for determination of total cell lipid weight. The TCA-insoluble lipid-extracted residues were dried, dissolved in I ml of NaOH, and their radioactivity determined. The latter was taken to represent cellular uptake of '25l-labeled lipoprotein.
To measure lipoprotein degradation the medium was precipitated with 10% TCA. Fig. 1 . Apo E was present in HDL2 isolated from plasma of normal individuals but was clearly missing in the HDL2 isolated from the apo E-deficient (apo EO) patient. The apoproteins of HDL3 from both the normal and apo Eo individuals showed similar polyacrylamide gel patterns, indicating the absence of apo E in our normal HDL3 ultracentrifugal preparations.
The interaction of normal 1251I-HDL2 and 1251I-HDL3 by adipocytes isolated from human fat tissue was assayed after 4 h of incubation with 10 sg/ml 1251I-labeled HDL at 37°C. (Fig. 4 A) and 65% of HDL3 (Fig. 4 B) (Fig. 4 A) and 80% of HDL3 (Fig. 4 B) (26) . High salt, however, affected LDL and HDL binding differently. Table III shows that HDL2 and HDL3 specific binding was reduced The possible role of apo E in the recognition of lipoproteins by human adipocyte membranes was investigated using apo E-free HDL2 and apo E-free HDL3 fractions isolated from the plasma of a patient genetically deficient in apo E (apo Eo; Fig.  1 ). The results in Table IV show that >90% of normal 125I-HDL3 binding was inhibited by excess normal HDL2 or HDL3 
Discussion
The present study extends our previous work on LDL interaction with adipocytes (23, 26) and demonstrates that human Adipocyte plasma membranes were obtained from properitoneal fat tissues as described in Methods. 10 ug (protein) adipocyte membranes were incubated with 40 Ag/ml '251-labeled lipoprotein (control). Parallel assays contained, in addition, 100-fold protein excess of the indicated unlabeled lipoprotein. Each value represents the average of duplicate assays. Normal and apo ED '251-HDL3 bound specifically to adipocyte membranes. Both bindings were partially inhibited by unlabeled LDL but were completely inhibited by HDL2 and by each other. These results suggest that HDL2 and HDL3 probably bind to the same site and that apo E is not required for binding. The various unlabeled HDL particles also completely inhibited '251-LDL binding. contributed to a nondisplaceable portion of surface-bound HDL particles. The role of apo E in the binding of HDL to human adipocytes was explored using apo E poor normal HDL3, apo EO-HDL2, and apo EO-HDL3 obtained from a patient with genetic apo E deficiency. All these apo E poor or deficient HDL particles bound specifically to human fat cells and to purified plasma membranes with similar affinity (Table VI) . This suggests that the presence of apo E is not obligatory for HDL adipocyte interactions. Apo EO-HDL2, apo EO-HDL3, normal HDL2, and normal HDL3 binding were all partially inhibited by unlabeled LDL, which indicated that the crosscompetition between LDL and HDL particles is not dependent on an apo E or apo B-E type of recognition (22, 48) . This conclusion is further substantiated by our finding that abeta- We conclude from our present study that human adipose tissue, functioning through its lipoprotein binding sites or domain, is probably an important site of interaction for both low and high density lipoproteins in vivo. The lower than normal level of plasma HDL-cholesterol (50) (51) (52) (53) and the increased rate of LDL turnover (54) observed in obesity might in fact be explained in part by an increase in lipoprotein metabolism by the expanded adipose mass in these individuals. Fong, Rodrigues, Salter, Yip, Despres, Gregg, and Angel 
